Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Attitudes Associated to Prescription of ADHD Drugs Among Child and Adolescent Psychiatrists in Region Skåne.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04799886
Recruitment Status : Not yet recruiting
First Posted : March 16, 2021
Last Update Posted : September 14, 2021
Sponsor:
Collaborator:
Region Skane
Information provided by (Responsible Party):
Lund University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Each year Region Skåne in Sweden gathers information on drug prescriptions within the region. The last ten years a significant pattern of uneven prescription rates of ADHD drugs to people up to 17 years of age are noticed in the different districts. These regional differences are noticed in other regions in Sweden as well and internationally.

The convention on the rights of the child became an institutional law in Sweden in 2020 and it emphasises that each child has the right to equal care and treatment. Therefore it is of importance to analyse how the variations in prescriptions rates arise and if we as healthcare providers can influence it. Our study is a collaboration between Region Skåne and the university of Lund and is a part of a larger study of the regional variations of prescriptions of ADHD drugs. Previous research informs us that a complex interplay of multiple factors can be behind variations in prescription rates among medical doctors and not the least subjective experiences and attitudes.

Our study performs semistructured interviews of Region Skånes child and adolescent psychiatrists with questions specifically regarding their own experiences and attitudes that might influence their prescription behavior.

The intention is to gather information that can guide future research questions.


Condition or disease Intervention/treatment
Attitude ADHD - Combined Type Physician's Role Other: Semi structured interview

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Ecologic or Community
Time Perspective: Other
Official Title: Attitudes Associated to Prescription of ADHD Drugs Among Child and Adolescent Psychiatrists in Region Skåne.
Estimated Study Start Date : October 1, 2021
Estimated Primary Completion Date : December 1, 2021
Estimated Study Completion Date : March 1, 2022
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Child and adolescent psychiatrist Other: Semi structured interview
Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Attitudes and experiences associated with prescription and diagnosis of ADHD [ Time Frame: 1 day (During the analysis of the transcribed interview) ]
    Semistructured interview


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All child and adolescent psychiatrists in Region Skåne are informed about the study and ask for participation.
Criteria

Inclusion Criteria:

  • child and adolescent psychiatrist in Region Skåne

Exclusion Criteria:

  • part of the research group
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04799886


Contacts
Layout table for location contacts
Contact: DAVID SJÖSTRÖM, MD 0046739075390 sjostrom.david@gmail.com
Contact: PEIK GUSTAFSSON, PHD 0046769250674 peik.gustafsson@med.lu.se

Sponsors and Collaborators
Lund University
Region Skane
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Lund University
ClinicalTrials.gov Identifier: NCT04799886    
Other Study ID Numbers: RSLUAFADHD2021
First Posted: March 16, 2021    Key Record Dates
Last Update Posted: September 14, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No